Clarifying the Role of the Mantel-Haenszel Risk Difference Estimator in Randomized Clinical Trials
Xiaoyu Qiu,Yuhan Qian,Jaehwan Yi,Jinqiu Wang,Yu Du,Yanyao Yi,Ting Ye
DOI: https://doi.org/10.48550/arXiv.2408.12541
2024-08-23
Abstract:The Mantel-Haenszel (MH) risk difference estimator, commonly used in randomized clinical trials for binary outcomes, calculates a weighted average of stratum-specific risk difference estimators. Traditionally, this method requires the stringent assumption that risk differences are homogeneous across strata, also known as the common risk difference assumption. In our article, we relax this assumption and adopt a modern perspective, viewing the MH risk difference estimator as an approach for covariate adjustment in randomized clinical trials, distinguishing its use from that in meta-analysis and observational studies. We demonstrate that the MH risk difference estimator consistently estimates the average treatment effect within a standard super-population framework, which is often the primary interest in randomized clinical trials, in addition to estimating a weighted average of stratum-specific risk difference. We rigorously study its properties under both the large-stratum and sparse-stratum asymptotic regimes. Furthermore, for either estimand, we propose a unified robust variance estimator that improves over the popular variance estimators by Greenland and Robins (1985) and Sato et al. (1989) and has provable consistency across both asymptotic regimes, regardless of assuming common risk differences. Extensions of our theoretical results also provide new insights into the Cochran-Mantel-Haenszel test and the post-stratification estimator. Our findings are thoroughly validated through simulations and a clinical trial example.
Methodology